Purpose: To report reflux of anti-VEGF drug during intravitreal injections.
Method: Review of electronic case notes of patients undergoing intra-vitreal anti-VEGF treatments. Prospective data collection was performed with a specific emphasis on presence or absence of reflux.
Results: 152 records of 102 eyes were available from an 8-month period. 119 Ranibizumab injections and 33 bevazicumab injections were considered. Reflux was noted in 48 injections (31%). For eyes with first injection of anti-VEGF agent, reflux was noted in 9/23 eyes. Eyes with at least one previous injection were observed to have reflux in 24/79 eyes. Presence of reflux was statistically tested against posterior vitreous detachment and phakic status and was found to be statistically insignificant.
Conclusion: Intra-vitreal anti-VEGF injections with volumes of 0.05 ml appears to produce displacement of the conjunctiva with a transient fluid-filled bleb immediately after the injection in approximately 1/3 of eyes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/08820538.2011.588648 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inflammation and Vasculitis Related to Brolucizumab.
J Clin Med
September 2024
Ophtalmology Department, Centro Hospitalar de Leiria, 2410-197 Leiria, Portugal.
: To compare the prevalence of intra-ocular inflammation (IOI) between brolucizumab and aflibercept in neovascular age-related macular degeneration (nAMD) after intra-vitreal injections (IVI) and to compare the IOI odds ratios (ORs) of both therapies with the prevalence of septic endophthalmitis after IVI that was previously reported in the literature. : A total of 468 IVI of brolucizumab (117 eyes) were compared with 2884 IVI of aflibercept (305 eyes) regarding IOI and occlusive retinal vasculitis (RV) from December 2021 to June 2023 in this retrospective study. The OR was calculated for both anti-VEGF agents and was compared with the relative risk of septic endophthalmitis after IVI.
View Article and Find Full Text PDFAdvanced Technologies of Drug Delivery to the Posterior Eye Segment Targeting Angiogenesis and Ocular Cancer.
Crit Rev Ther Drug Carrier Syst
November 2023
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, Mumbai 400056, India.
Retinoblastoma (RB), a childhood retinal cancer is caused due to RB1 gene mutation which affects the child below 5 years of age. Angiogenesis has been proven its role in RB metastasis due to the presence of vascular endothelial growth factor (VEGF) in RB cells. Therefore, exploring angiogenic pathway by inhibiting VEGF in treating RB would pave the way for future treatment.
View Article and Find Full Text PDFRetinal detachment following retinopathy of prematurity in France: Screening and treatment pathways.
Acta Paediatr
December 2023
Pediatric Ophthalmology Department, Rothschild Foundation Hospital, Paris, France.
Aim: Preterm children are highly vulnerable to sensorial impairments through Retinopathy Of Prematurity (ROP). The objective was to determine whether some cases of ROP requiring surgery could be secondary to deficiencies in care pathways.
Methods: Descriptive study of neonatal characteristics and the screening/treatment pathways of children treated for stage ≥4A ROP from 2009 to 2020 in a referral unit in France.
Influencing factors of low vision 2 years after vitrectomy for proliferative diabetic retinopathy: an observational study.
BMC Ophthalmol
July 2023
School of Clinical and Basic Medicine, Shandong First Medical University (Shandong Academy of Medical Sciences), Taian, 271000, Shandong, People's Republic of China.
Background: Proliferative diabetic retinopathy (PDR) can seriously affect the vision and quality of life of patients. The present study aimed to evaluate the clinical effect of vitrectomy for PDR by observing visual recovery and postoperative complications and to explore the factors influencing low vision.
Methods: This was a case series observational study.
A systematic review and meta-analysis of randomised controlled trials in the management of neovascular glaucoma: absence of consensus and variability in practice.
Graefes Arch Clin Exp Ophthalmol
February 2023
The Medical School, Guy's King's & St Thomas' Medical School, King's College London, University of London, London, UK.
Purpose: Neovascular glaucoma (NVG) is characterised by neovascularisation of the angle and therefore elevated intraocular pressure (IOP). This results in progressive optic neuropathy and loss of visual acuity. Treatment aims to reduce IOP in order to prevent optic nerve damage.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!